Novel therapeutic approaches for hepatitis C. (Q38152674)

29 August 2017

Novel therapeutic approaches for hepatitis C. (English)

1 reference

29 August 2017

J S Au

1

1 reference

29 August 2017

P J Pockros

series ordinal

2

1 reference

29 August 2017

language of work or name

English

0 references

publication date

14 October 2013

1 reference

Clinical Pharmacology & Therapeutics

29 August 2017

1 reference

29 August 2017

95

1 reference

29 August 2017

1

1 reference

29 August 2017

78-88

1 reference

https://scigraph.springernature.com/pub.10.1038/clpt.2013.206

29 August 2017

0 references

cites work

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.206

Expanded hepatitis C virus screening recommendations promote opportunities for care and cure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.206

Genetic diversity and evolution of hepatitis C virus--15 years on

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.206

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.206

Boceprevir for untreated chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.206

A watershed moment in the treatment of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.206

Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.206

New direct-acting antivirals in the development for hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.206

Telaprevir for previously untreated chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.206

Telaprevir for previously treated chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.206

Boceprevir for previously treated chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.206

Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.206

Evaluating the role of macrocycles in the susceptibility of hepatitis C virus NS3/4A protease inhibitors to drug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.206

What are the promising new therapies in the field of chronic hepatitis C after the first-generation direct-acting antivirals?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.206

Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.206

Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.206

Viral resistance in hepatitis C virus genotype 1-infected patients receiving the NS3 protease inhibitor Faldaprevir (BI 201335) in a phase 1b multiple-rising-dose study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.206

Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.206

Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype 1 HCV: SILEN-C1 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.206

Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.206

MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.206

Phosphorylation of hepatitis C virus nonstructural protein 5A modulates its protein interactions and viral RNA replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.206

Regulation of Hepatitis C Virion Production via Phosphorylation of the NS5A Protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.206

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.206

Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.206

A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.206

Chronic hepatitis C: treatments of the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.206

PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.206

Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.206

Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.206

Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.206

Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.206

Sofosbuvir for previously untreated chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.206

PROPEL: a randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-naïve HCV genotype 1/4 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.206

JUMP-C: a randomized trial of mericitabine plus pegylated interferon alpha-2a/ribavirin for 24 weeks in treatment-naïve HCV genotype 1/4 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.206

Antiviral effect, safety, and pharmacokinetics of five-day oral administration of Deleobuvir (BI 207127), an investigational hepatitis C virus RNA polymerase inhibitor, in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.206

Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.206

Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.206

The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.206

Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.206

Faldaprevir and deleobuvir for HCV genotype 1 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.206

Exploratory study of oral combination antiviral therapy for hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.206

Combination treatment with hepatitis C virus protease and NS5A inhibitors is effective against recombinant genotype 1a, 2a, and 3a viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.206

Preliminary study of two antiviral agents for hepatitis C genotype 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.206

Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.206

AFP-specific immunotherapy impairs growth of autochthonous hepatocellular carcinoma in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.206

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/CLPT.2013.206

1 reference

Dimensions Publication ID

29 August 2017

0 references

1 reference